Navigation Links
Monogram Announces First Medicare Payment for Trofile(TM)
Date:9/24/2007

y cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to the market acceptance of Selzentry and ongoing and future clinical trials of Selzentry; whether competitive tropism assays are developed and commercialized by others; whether third party payers will provide coverage and reimbursement for the Trofile Assay; the level of reimbursement that third party payers will authorize for Trofile; risks related to the implementation of the collaboration with Pfizer; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials for CCR5 inhibitors or entry inhibitors; the use of our Trofile Assay for patient use with Selzentry; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payors will authorize reimbursement for our products and services; whether the FDA or any other agency will decide to further regulate our products or services; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause our actual events to differ from those projected, please r
'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Monogram Presents Results of First ETag Breast Cancer Studies
2. PM announces a new health care order for India
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Pasadena sleep apnea ... for sleep apnea. Drowsy drivers are 15 times more ... are well-rested, and some experts believe that sleep-deprived drivers ... intoxicated drivers. Unfortunately, millions of Americans may be sleep-deprived ... of Sleep Medicine, about 18 million Americans have sleep ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley ... to provide logistics and support for one of Dallas’ ... a long history of giving back to the community in ... year's Toy Drive were Whataburger® and 99.5 The Wolf. , ... holidays. Providing gifts to children who would otherwise not receive ...
(Date:12/22/2014)... A substantial percentage of patients ... (CT) to evaluate abnormal findings on outpatient chest ... to a new study published online in the ... show that radiologist recommendations for additional imaging (RAIs) ... care. , RAIs, which have grown 200 percent ...
(Date:12/21/2014)... In this report, the global ... source, product, and application. The market, by power ... instruments. By product, the market covers the handpieces; ... handpieces market is further subdivided into drills, saws, ... instruments, shavers, wire/pin drivers, and others. Moreover, the ...
(Date:12/21/2014)... Hills, Ca (PRWEB) December 21, 2014 ... Khanna was a guest at the Aspen Helicopters holiday ... kids and a Santa with sleigh, flown by an ... helicopter appeared invisible; only Santa with sleigh was visible.(please ... during day and night. Dr.Khanna has helped many pilots ...
Breaking Medicine News(10 mins):Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... from Spain to Lithuania, thirteen research institutes from eleven European ... was Professor Dr Jeroen Buters of TUM,s Chair of Molecular ... mission was to study the three main causes of hay ... trees, grass and olive plants. Sufferers develop allergic symptoms when ...
... Rochelle, NY, May 21, 2012Currently more than 10% of ... that target pregnancy, infancy, and toddlers are urgently needed ... as proposed in an article in Childhood Obesity ... publishers. The article is available free online ahead of ...
... - Environmental scientists at Harvard have discovered that the ... by both atmospheric forces and the flow of circumpolar ... Ocean. While the atmospheric source was previously recognized, ... comes from the rivers. The revelation implies that ...
... mei 2012 - VIB researcher Diether Lambrechts, associated with ... predict which patients will benefit more from treatment with ... important step towards personalized medicine and patient-tailored use of ... KU Leuven) said "in two large clinical studies with ...
... limits sexual activity is common among older patients with ... "We compared measures of well-being, depression and sexual function ... both of which are associated with dypnea during exertion," ... Hospital in Denmark. "A significantly higher percentage of COPD ...
... more intensely than walking without poles. The research ... , 19-22 May, in Belgrade, Serbia. The Congress is ... of the European Society of Cardiology., Aerobic ... life and reduces heart failure related hospitalisations. However, many ...
Cached Medicine News:Health News:Some pollens are much more aggressive than others 2Health News:A systems approach to preventing obesity in early life 2Health News:Toxic mercury, accumulating in the Arctic, springs from a hidden source 2Health News:Toxic mercury, accumulating in the Arctic, springs from a hidden source 3Health News:Toxic mercury, accumulating in the Arctic, springs from a hidden source 4Health News:Biomarker predicts response to cancer treatment 2Health News:Troublesome dyspnea during sexual activity is common in COPD patients 2Health News:Nordic walking improves health of heart failure patients 2
(Date:12/22/2014)... NEW YORK , Dec. 22, 2014 /PRNewswire/ ... developing novel therapies for the treatment of chronic ... subjects has been dosed in a pharmacokinetic and ... receptor antagonist for neuropathic pain. Racemic ... treatment of various pain states and substitution therapy ...
(Date:12/19/2014)... 2014 TODAY, AEGATE, the leader ... announced the appointment of Peter Fox as ... Channels and Partner Officer. Peter has served ... its acquisition by Oracle in 2011. Prior ... Geneva and subsequently Convergys, a world renowned ...
(Date:12/19/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB:  ... in the development of brachytherapy devices and medical ... that a Life Sciences Discovery Fund (LSDF) Proof ... AMIC is the commercialization partner.  The award was ... proposal titled "Optimized Injectable Radiogels for High-dose Therapy ...
Breaking Medicine Technology:Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
... Schering-Plough Corporation,(NYSE: SGP ) today reported that ... Phase II study of boceprevir, its investigational oral ... chronic,hepatitis C virus (HCV) genotype 1 were presented ... for the Study of the Liver (EASL). The,ongoing ...
... Into New Promising Drugs to Combat Hepatitis ... C ... Stem Cells of Potential Benefit in Liver Transplantation, ... At today,s sessions of the 43rd Annual Meeting of the European,Association for the ...
Cached Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
The Storz Protege is an anterior segment unit only....
The CV-12000 provides the surgeon with all the options to perform today's newest techniques....
Phaco-emulsification systems CV series...
The unprecedented power, flexibility and versatility of the Series 20000 Legacy have made it the world's leading phacoemulsifier....
Medicine Products: